NYSE:EVH - Evolent Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.60
  • Forecasted Upside: 39.11 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.31 (-1.16%)

This chart shows the closing price for EVH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evolent Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVH

Analyst Price Target is $36.60
▲ +39.11% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Evolent Health in the last 3 months. The average price target is $36.60, with a high forecast of $50.00 and a low forecast of $25.00. The average price target represents a 39.11% upside from the last price of $26.31.

This chart shows the closing price for EVH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Evolent Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$26.00 ➝ $37.00High
11/4/2021Canaccord GenuityBoost Price TargetBuy$37.00 ➝ $50.00High
11/4/2021Piper SandlerBoost Price TargetOverweight$30.00 ➝ $36.00High
10/12/2021Canaccord GenuityBoost Price TargetBuy$27.00 ➝ $37.00Low
9/13/2021BTIG ResearchBoost Price TargetBuy$30.00 ➝ $35.00Medium
8/5/2021Canaccord GenuityBoost Price TargetBuy$24.00 ➝ $27.00High
8/5/2021Piper SandlerBoost Price TargetOverweight$29.00 ➝ $30.00High
5/6/2021Piper SandlerBoost Price TargetOverweight$27.00 ➝ $29.00High
4/29/2021JPMorgan Chase & Co.Initiated CoverageNeutralLow
3/1/2021Canaccord GenuityBoost Price TargetBuy$22.00 ➝ $24.00Low
2/26/2021CowenBoost Price TargetOutperform$19.00 ➝ $25.00High
2/26/2021BTIG ResearchBoost Price TargetBuy$20.00 ➝ $25.00High
2/26/2021Piper SandlerBoost Price TargetOverweight$25.00 ➝ $27.00High
1/19/2021Piper SandlerReiterated RatingPositive ➝ Overweight$15.00 ➝ $25.00N/A
1/7/2021Canaccord GenuityBoost Price TargetBuy$16.00 ➝ $20.00Low
1/6/2021BTIG ResearchInitiated CoverageBuy$20.00N/A
11/6/2020Piper SandlerLower Price TargetOverweight$16.00 ➝ $15.00Low
10/8/2020Piper SandlerLower Price TargetOverweight$17.00 ➝ $16.00Medium
9/30/2020Canaccord GenuityReiterated RatingBuyHigh
8/5/2020Canaccord GenuityBoost Price TargetIn-Line ➝ Buy$13.00 ➝ $16.00Low
8/5/2020Truist FinancialBoost Price TargetBuy$15.00 ➝ $20.00High
8/5/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Neutral$10.00 ➝ $13.00High
7/20/2020Robert W. BairdBoost Price TargetOutperform$10.00 ➝ $12.00Low
7/20/2020SunTrust BanksBoost Price TargetBuy$14.00 ➝ $15.00Low
7/20/2020Canaccord GenuityReiterated RatingBuy$13.00Medium
6/26/2020JPMorgan Chase & Co.Boost Price TargetNeutral$8.00 ➝ $11.00High
6/5/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$13.00 ➝ $8.00Low
6/2/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$9.00 ➝ $8.00High
6/1/2020Canaccord GenuityReiterated RatingBuy$17.00 ➝ $17.00High
6/1/2020Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$14.00 ➝ $9.00High
5/8/2020SunTrust BanksBoost Price TargetBuy$12.00 ➝ $14.00High
3/26/2020SunTrust BanksLower Price TargetBuy$16.00 ➝ $12.00High
2/26/2020Piper SandlerBoost Price TargetOverweight$10.15 ➝ $17.00Low
2/26/2020Cantor FitzgeraldReiterated RatingOverweight$16.00 ➝ $14.00High
2/13/2020Canaccord GenuityReiterated RatingBuy$19.00High
1/23/2020Cantor FitzgeraldBoost Price TargetOverweight$10.00 ➝ $16.00High
1/8/2020Wells Fargo & CompanyLower Price TargetOverweight$19.00 ➝ $17.00Medium
12/30/2019Cantor FitzgeraldReiterated RatingBuy$10.00High
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$10.15High
12/4/2019SunTrust BanksReiterated RatingBuy$14.00Low
12/2/2019KeyCorpLower Price TargetOverweight$20.00 ➝ $10.00High
11/27/2019Piper Jaffray CompaniesReiterated RatingOverweight$10.15High
11/27/2019Cantor FitzgeraldReiterated RatingOverweight$16.00 ➝ $10.00High
11/6/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $12.00High
9/10/2019Piper Jaffray CompaniesSet Price TargetBuy$10.00High
8/7/2019Piper Jaffray CompaniesSet Price TargetBuy$10.00Low
8/7/2019CowenSet Price TargetBuy$18.00Low
8/7/2019OppenheimerSet Price TargetBuy$15.00Low
8/7/2019Cantor FitzgeraldSet Price TargetOverweight$18.00 ➝ $16.00High
3/4/2019KeyCorpLower Price TargetOverweight ➝ Overweight$32.00 ➝ $20.00High
2/27/2019OppenheimerLower Price TargetOutperform$31.00 ➝ $21.00Low
2/27/2019Wells Fargo & CompanyLower Price TargetOutperform$34.00 ➝ $21.50High
2/27/2019Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$37.00 ➝ $20.00High
12/31/2018Cantor FitzgeraldReiterated RatingBuy$37.00Low
11/7/2018Wells Fargo & CompanyBoost Price TargetOutperform$26.00 ➝ $34.00High
11/7/2018Piper Jaffray CompaniesReiterated RatingOverweight$34.00High
10/5/2018SVB LeerinkSet Price TargetOutperform ➝ Buy$35.00Medium
10/4/2018CitigroupBoost Price TargetPositive ➝ Buy$25.00 ➝ $32.00Medium
9/13/2018Canaccord GenuityBoost Price TargetBuy$24.00 ➝ $28.00Low
9/13/2018KeyCorpReiterated RatingOverweight$28.00 ➝ $32.00High
9/13/2018CowenBoost Price TargetOutperform$29.00 ➝ $35.00High
9/12/2018Cantor FitzgeraldReiterated RatingBuy$37.00Medium
8/20/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $28.00Low
8/7/2018Jefferies Financial GroupReiterated RatingBuy$25.00High
6/7/2018SunTrust BanksBoost Price TargetBuyLow
6/7/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$24.00 ➝ $26.00High
6/4/2018Piper Jaffray CompaniesInitiated CoverageOverweight$30.00High
5/30/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$19.00 ➝ $24.00High
2/28/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$27.00 ➝ $24.00High
2/28/2018Wells Fargo & CompanyLower Price TargetOutperform$27.00 ➝ $20.00Low
2/13/2018Jefferies Financial GroupSet Price TargetBuy$22.00Low
1/4/2018CitigroupInitiated CoverageBuyHigh
12/3/2017Cantor FitzgeraldReiterated RatingBuy$30.00Low
11/18/2017SVB LeerinkSet Price TargetBuy$25.00N/A
11/7/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyN/A
11/3/2017SunTrust BanksReiterated RatingBuy$30.00N/A
11/2/2017Cantor FitzgeraldReiterated RatingBuy$30.00N/A
11/1/2017Robert W. BairdReiterated RatingBuy$25.00N/A
10/6/2017Canaccord GenuityReiterated RatingBuy$32.00N/A
10/6/2017CowenReiterated RatingOutperform$33.00 ➝ $29.00N/A
9/26/2017Robert W. BairdReiterated RatingOutperform$35.00 ➝ $25.00High
9/20/2017SunTrust BanksReiterated RatingBuy$30.00Low
9/19/2017KeyCorpInitiated CoverageOverweight ➝ Overweight$23.00Low
9/6/2017Jefferies Financial GroupReiterated RatingBuy$28.00Low
8/18/2017SVB LeerinkSet Price TargetBuy$32.00Low
8/18/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
8/9/2017CowenReiterated RatingOutperform$35.00 ➝ $33.00High
8/8/2017Robert W. BairdSet Price TargetBuy$35.00High
6/28/2017CowenReiterated RatingOutperform$35.00Low
6/19/2017SVB LeerinkReiterated RatingOutperform$30.00 ➝ $32.00Low
6/14/2017Robert W. BairdReiterated RatingOutperform$30.00 ➝ $35.00Medium
6/1/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$30.00High
4/13/2017Jefferies Financial GroupReiterated RatingBuy$28.00Low
3/14/2017CIBCInitiated CoverageOutperform ➝ OutperformLow
3/13/2017OppenheimerInitiated CoverageOutperform$28.00Low
3/8/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$30.00Medium
3/1/2017Cantor FitzgeraldReiterated RatingBuy$26.00N/A
2/28/2017SVB LeerinkSet Price TargetBuy$24.00N/A
2/3/2017Canaccord GenuityReiterated RatingBuy$31.00N/A
1/16/2017Jefferies Financial GroupSet Price TargetBuy$28.00N/A
1/13/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
1/5/2017Cantor FitzgeraldInitiated CoverageOverweight$26.00N/A
(Data available from 12/4/2016 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.
Evolent Health logo
Evolent Health, Inc. engages in the provision of health care delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.
Read More

Today's Range

Now: $26.31
Low: $25.75
High: $26.70

50 Day Range

MA: $29.12
Low: $25.36
High: $34.11

52 Week Range

Now: $26.31
Low: $14.60
High: $34.60


606,410 shs

Average Volume

576,215 shs

Market Capitalization

$2.35 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Evolent Health?

The following Wall Street research analysts have issued research reports on Evolent Health in the last twelve months: BTIG Research, Canaccord Genuity, Cowen Inc, JPMorgan Chase & Co., Piper Sandler, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for EVH.

What is the current price target for Evolent Health?

5 Wall Street analysts have set twelve-month price targets for Evolent Health in the last year. Their average twelve-month price target is $36.60, suggesting a possible upside of 39.1%. Canaccord Genuity has the highest price target set, predicting EVH will reach $50.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $25.00 for Evolent Health in the next year.
View the latest price targets for EVH.

What is the current consensus analyst rating for Evolent Health?

Evolent Health currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVH will outperform the market and that investors should add to their positions of Evolent Health.
View the latest ratings for EVH.

What other companies compete with Evolent Health?

Other companies that are similar to Evolent Health include R1 RCM, Premier, Terminix Global, ManTech International, Franklin Covey, PHI Group, Jupai, Rainmaker Systems and Taylor Consulting.

How do I contact Evolent Health's investor relations team?

Evolent Health's physical mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company's listed phone number is (571) 389-6000 and its investor relations email address is [email protected] The official website for Evolent Health is www.evolenthealth.com.